A Phase 2 Study of Actinium-225 (Ac-225)-Lintuzumab in Older Patients with Untreated Acute Myeloid Leukemia (AML) - Interim Analysis of 1.5 mu ci/Kg/Dose Article
Full Text via DOI: 10.1182/blood-2018-99-111951
Web of Science: 000454837604128